Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics


Mirum Pharmaceuticals, Inc. - common stock (MIRM): $18.89

0.61 (+3.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIRM POWR Grades

  • MIRM scores best on the Value dimension, with a Value rank ahead of 72.4% of US stocks.
  • MIRM's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • MIRM's current lowest rank is in the Quality metric (where it is better than 4.64% of US stocks).

MIRM Stock Summary

  • MIRM's price/sales ratio is 14.07; that's higher than the P/S ratio of 92.44% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MIRUM PHARMACEUTICALS INC is reporting a growth rate of -80.05%; that's higher than only 17.15% of US stocks.
  • As for revenue growth, note that MIRM's revenue has grown 226.84% over the past 12 months; that beats the revenue growth of 96.24% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MIRUM PHARMACEUTICALS INC are FOLD, GWH, APLS, VLDR, and API.
  • MIRM's SEC filings can be seen here. And to visit MIRUM PHARMACEUTICALS INC's official web site, go to mirumpharma.com.

MIRM Valuation Summary

  • In comparison to the median Healthcare stock, MIRM's price/sales ratio is 191.67% higher, now standing at 14.
  • Over the past 41 months, MIRM's EV/EBIT ratio has gone down 15.5.

Below are key valuation metrics over time for MIRM.

Stock Date P/S P/B P/E EV/EBIT
MIRM 2022-11-25 14.0 4.3 -17.6 -22.4
MIRM 2022-11-23 13.8 4.3 -17.3 -22.1
MIRM 2022-11-22 13.9 4.3 -17.4 -22.3
MIRM 2022-11-21 13.6 4.2 -17.0 -21.8
MIRM 2022-11-18 13.8 4.3 -17.4 -22.2
MIRM 2022-11-17 13.9 4.3 -17.5 -22.3

MIRM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MIRM has a Quality Grade of C, ranking ahead of 49.16% of graded US stocks.
  • MIRM's asset turnover comes in at 0.052 -- ranking 319th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MIRM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.052 1 -0.949
2021-03-31 0.000 NA -1.229
2020-12-31 0.000 NA -1.146
2020-09-30 0.000 NA -0.934
2020-06-30 0.000 NA -0.781
2020-03-31 0.000 NA -0.694

MIRM Price Target

For more insight on analysts targets of MIRM, see our MIRM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.29 (Strong Buy)

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $18.89 52-week high $30.55
Prev. close $18.28 52-week low $12.95
Day low $18.00 Volume 365,765
Day high $18.91 Avg. volume 275,941
50-day MA $20.58 Dividend yield N/A
200-day MA $22.86 Market Cap 696.47M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about MIRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals Provides Development Program Updates

FOSTER CITY, Calif., November 29, 2022--Mirum Pharmaceuticals Provides Development Program Updates

Yahoo | November 29, 2022

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif., November 18, 2022--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Yahoo | November 18, 2022

The Mirum Pharmaceuticals Inc. (MIRM) had a good session last reading, didn’t it?

The share price of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) fell to $20.02 per share on Wednesday from $23.94. While Mirum Pharmaceuticals Inc. has underperformed by -16.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MIRM rose by 26.47%, with highs and lows ranging from $30.55 to $12.82, […]

US Post News | November 10, 2022

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire | November 9, 2022

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (NASDAQ:NASDAQ:MIRM) Q3 2022 Results Conference Call November 09, 2022 08:00 AM ET Company Participants Ian Clements - CFO Chris Peetz - President, CEO &…

Seeking Alpha | November 9, 2022

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo -18.72%
3-mo -24.53%
6-mo -25.13%
1-year 39.20%
3-year 130.93%
5-year N/A
YTD 18.43%
2021 -8.65%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6648 seconds.